Berenberg Bank Issues Positive Forecast for Haleon (LON:HLN) Stock Price

Haleon (LON:HLN) had its price target raised by Berenberg Bank from GBX 510 to GBX 512 in a research note released on Thursday, Marketbeat Ratings reports. They currently have a buy rating on the stock.

A number of other brokerages have also weighed in on HLN. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Jefferies Financial Group reiterated a “buy” rating and set a GBX 450 price objective on shares of Haleon in a research note on Wednesday, January 21st. Finally, JPMorgan Chase & Co. increased their target price on Haleon from GBX 315 to GBX 335 and gave the company an “underweight” rating in a report on Wednesday, November 26th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of GBX 407.

Haleon Stock Performance

LON:HLN opened at GBX 378.50 on Thursday. The company has a debt-to-equity ratio of 53.60, a quick ratio of 0.93 and a current ratio of 0.87. The stock has a market capitalization of £33.71 billion, a PE ratio of 20.46, a P/E/G ratio of 1.49 and a beta of 0.25. Haleon has a fifty-two week low of GBX 325.10 and a fifty-two week high of GBX 419.50. The company has a fifty day moving average of GBX 385.67 and a two-hundred day moving average of GBX 367.32.

Haleon (LON:HLN) last announced its earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share (EPS) for the quarter. Haleon had a net margin of 13.81% and a return on equity of 9.40%. As a group, research analysts forecast that Haleon will post 19.5033282 earnings per share for the current fiscal year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.